Legend Biotech ( (LEGN) ) has issued an update.
Legend Biotech announced on April 15, 2025, that its product CARVYKTI® achieved approximately $369 million in net trade sales for the quarter ending March 31, 2025. This preliminary sales figure, provided by Janssen Biotech, reflects the product’s market performance and potential impact on Legend Biotech’s financial results, although it remains unaudited and subject to further financial review.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech is experiencing significant revenue growth, driven by CARVYKTI’s expansion, but faces challenges in achieving profitability and managing cash flow. Earnings call insights and strategic expansions provide optimism for future performance, though current financial metrics reflect a need for caution.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation operates in the biotechnology industry, focusing on the development of innovative cell therapies. Their primary product, CARVYKTI®, is a treatment developed in collaboration with Janssen Biotech, Inc., targeting specific cancer indications.
YTD Price Performance: -7.54%
Average Trading Volume: 1,233,370
Technical Sentiment Signal: Buy
Current Market Cap: $5.9B
See more insights into LEGN stock on TipRanks’ Stock Analysis page.